Vectus Biosystems Ltd
VBS
Company Profile
Business description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including cardio, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
Contact
26-34 Dunning Avenue
Unit 5, Ground Floor
Rosebery
SydneyNSW2018
AUST: +61 283441300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
Samsung and SK Hynix lead chip selloff as China competition fears grow
CXMT’s claimed tech breakthrough and an AI industry leader’s comments are weighing on stocks across the sector.
stocks
Updating our assumed commodity prices and fair values of the two largest Aussie miners
Stronger copper, aluminum and zinc prices offset by iron ore.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,894.10 | 27.40 | -0.31% |
| CAC 40 | 7,827.63 | 5.25 | -0.07% |
| DAX 40 | 25,259.90 | 17.78 | -0.07% |
| Dow JONES (US) | 51,670.10 | 180.45 | -0.35% |
| FTSE 100 | 10,650.33 | 5.95 | -0.06% |
| HKSE | 24,345.22 | 74.02 | 0.30% |
| NASDAQ | 27,204.38 | 41.52 | -0.15% |
| Nikkei 225 | 67,777.52 | 1,253.40 | -1.82% |
| NZX 50 Index | 13,658.57 | 91.03 | -0.66% |
| S&P 500 | 7,805.45 | 1.79 | -0.02% |
| S&P/ASX 200 | 8,753.20 | 30.70 | -0.35% |
| SSE Composite Index | 3,800.86 | 3.62 | 0.10% |